卵巢上皮性肿瘤中Skp2、p27kipl、E-cad的表达

目的检测Skp2、p27kipl和E-cad在卵巢上皮性肿瘤中的表达情况及其相互关系。方法采用免疫组化SP法，检测99例卵巢上皮性肿瘤组织中Skp2、p27kipl及E-cad的表达。结果p27kipl在卵巢良性肿瘤、交界性肿瘤的表达率分别为76．5％、70．6％高于卵巢癌29．2％（P〈0．05），在早期癌中的表达高于晚期癌（P〈0．05）。Skp2在卵巢良性肿瘤、交界性肿瘤的表达率分别为0、23．5％，均低于卵巢癌50．8％（P〈0．05），在早期癌的表达低于晚期癌（P〈0．05）。卵巢癌中skp2表达与组织分化有关，在低分化癌的阳性表达率高于高分化癌（P〈0．05），在组织学类型方面，浆液性癌中skp2的阳性表达率高于非浆液性癌（P〈0．05）。E—cad在良性肿瘤、交界性肿瘤和卵巢癌表达率分别为88．2％、82．4％、55．4％，恶性组低于良性组（P〈0．05）。E—cad在早期癌的表达率高于晚期癌（P〈0．05）。Skp2表达与p27kipl表达呈负相关（P〈0．05），E-cad表达与p27kipl表达呈正相关（P〈0．05），而E-cad表达与Skp2表达则呈负相关（P〈0．05）。结论skp2过度表达与p27kipl表达减少可能与卵巢上皮性肿瘤的发生发展密切相关，而E-cad在晚期卵巢癌中表达降低可能反映了卵巢癌分化程度的降低。     

PTEN蛋白和FHIT蛋白在上皮性卵巢癌中的表达及临床病理意义

目的检测抑癌基因蛋白PTEN、FHIT表达在卵巢癌发展中的作用及相关病理机制。方法采用免疫组化法检测45例卵巢癌组织、10例卵巢交界性肿瘤、10例卵巢良性肿瘤、5例正常卵巢组织中PTEN和FHIT蛋白表达，并比较这两种蛋白表达与临床病理特征的关系。结果卵巢癌和交界性卵巢肿瘤组织中PTEN蛋白和FHIT蛋白表达显著低于卵巢囊肿和正常卵巢（P〈0．05），在上皮性卵巢癌中这两种蛋白表达与组织分化程度正相关（P〈0．05），它们表达降低或失活与卵巢癌淋巴结转移相关（P〈0．005），但与组织学类型无显著相关性。PTEN蛋白表达与恶性肿瘤临床分期负相关．FHIT蛋白表达与临床分期无显著相关性。这两种蛋白在上皮性卵巢癌中表达的相关性有统计学意义（P=0．0343）。结论在卵巢癌发生过程中PTEN蛋白表达降低起到重要作用，预示着卵巢癌的不良预后；FHIT蛋白缺失是恶性上皮性卵巢肿瘤的特征，其表达缺失在卵巢肿瘤的发生发展中起一定作用，可能与上皮性卵巢癌的恶性进展及转移有关．这两种蛋白可能协同促进卵巢癌的发生、发展、浸润及转移。     

HER-2/neu在卵巢上皮性肿瘤中的表达及意义

目的 研究HER－2／neu（c-erbB-2)在卵巢上皮性肿瘤中的表达及意义。方法 收集106例卵巢上皮性肿瘤（恶性54例,交界性33例,良怀19例）及临床资料。按国际妇产科联合会（FIGO）标准进行分期,卵巢癌中Ⅰ,Ⅱ期中19例（19／54,35．2％）,Ⅲ,Ⅳ期共35例（35／54,64．8％）,交界性肿瘤均为Ⅰ期。采用标记链霉素卵白素生物素（LSAB）法用HER－2／neu多克隆抗体（DAKO,A0485）行免疫组织化学染色。结果 该蛋白表达的阳性率在良性肿瘤为47．4％（9／19）,过表达（3＋）为0;交界性肿瘤为84．8％（28／33）,过表达率为9．15（3／33）,恶性肿瘤为85．2％（46／54）,过表达率为25．9％（14／54）。良性与交界性以及良性与恶性之间的HER－2／neu蛋白表达率的差异有显著性（P＜0．02,P＜0．01）;该蛋白的过表达率在有转移和无转移的病例之间差异有显著性意义（P＜0．001）。结论 HER－2／neu的过表达与卵巢癌的侵袭性生物学行为相关。     

卵巢肿瘤组织p73蛋白表达的研究

目的研究卵巢上皮性肿瘤组织中p73蛋白的表达,探讨它们在卵巢肿瘤发生发展中的作用。方法应用免疫组化SP法检测p73蛋白在15例良性,12例交界性,50例恶性肿瘤和15例正常卵巢组织中的表达,用Pearsonχ2检验p73基因的表达在四组间是否有差别。结果p73蛋白在良性肿瘤中表达率为26.7%（2/15）;在交界性肿瘤阳性表达率为50%（6/12）;在恶性肿瘤阳性表达率为76%（38/50）;在正常组织表达率为13.3%（1/15）。恶性肿瘤与良性肿瘤,恶性肿瘤和正常组织间差异具有显著性（P〈0.05）;恶性肿瘤和交界性肿瘤间无明显相关性（P〉0.05）。p73蛋白表达与癌肿细胞分型相关：粘液性肿瘤p73以胞核阳性表达为主,浆液性肿瘤p73以胞浆阳性表达为主。结论突变型p73基因的高表达可作为判断卵巢上皮性肿瘤良、恶性的指标之一,p73基因的表达类型与细胞分型有关。     

卵巢上皮性肿瘤组织中HIF-1α与VEGF的表达及意义

目的探讨卵巢上皮性肿瘤组织中缺氧诱导因子-1α（hypoxia inducible factor-1α,HIF-1α）的表达水平及其与血管内皮生长因子（vascularendothelial growth factor,VEGF）的关系。方法采用原位杂交和免疫组化S-P法检测66例卵巢上皮性肿瘤组织和正常卵巢组织中HIF-1αmRNA和VEGF蛋白的表达情况。结果在卵巢上皮癌和交界性卵巢肿瘤组织中HIF-1αmRNA的表达水平明显高于良性卵巢上皮性肿瘤和正常卵巢组织（P〈0．05）,而且与肿瘤的病理学分级有关（P〈0．05）。HIF-1αmRNA的表达与VEGF有相关性。结论HIF-1α对卵巢上皮癌的发生、发展具有重要作用,它可通过介导VEGF的表达促进肿瘤新生血管形成,从而进一步促进肿瘤的生长和转移。     

血管内皮生长因子及其受体在卵巢癌中表达的免疫组化 …

目的;检测血管内皮生长因子（ＶＥＧＦ）及其受体（ＫＤＲ０在卵巢癌中的表达,并探讨其与卵巢癌发生的关系。方法：采用ＳＡＢＣ免疫组化染色法,对６６例卵巢肿瘤中,ＶＥＧＦ和ＫＤＲ的表达进行检测。结果：恶性,交界性及良性卵巢肿瘤中,ＶＥＧＦ和ＫＤＲ的表达率分别为７２．９％,７５．００Ａ％,３８．４６及５４．０５％,４３．７５％〈７．６９％;恶性肿瘤及交界性肿瘤ＶＥＧＦ和ＫＤＲ的表达,明显高于良性肿瘤。     

H3K9Ac在卵巢上皮性肿瘤中的表达及其临床意义

目的 研究组蛋白H3赖氨酸残基9位乙酰化（H3KgAc）在卵巢上皮性肿瘤中的表达及其与卵巢癌组织学分级、临床分期之间的关系。方法 采用免疫组织化学ABC法检测20例良性、16例交界性、40例恶性卵巢上皮性肿瘤中H3K9Ac的表达情况，并分析其与临床病理指标间的关系。结果 ①H3K9Ac在良性、交界性、恶性卵巢上皮性肿瘤中的表达逐渐降低，差异有显著统计学意义（P〈0．01）；②与粘液性囊腺癌相比，H3KgAc在浆液性囊腺癌中表达较低，差异有统计学意义（P〈0．05）；③H3KgAc的表达与卵巢上皮性癌的组织分化程度及临床分期有关，在Ⅲ、Ⅳ期卵巢癌中H3KgAc的表达明显低于Ⅰ、Ⅱ期卵巢癌（P〈0．01）；随着组织分化程度降低，H3KgAc表达也逐渐降低，两两比较差异有统计学意义（P〈0．05）。结论 H3KgAc在良性、交界性、恶性卵巢上皮性肿瘤中的表达差异显著，且随着卵巢上皮性癌恶性程度的增高，表达逐渐降低，H3K9Ac可能为卵巢上皮性肿瘤的良恶性及其预后判断提供一个新的生物学指标。     

基质金属蛋白酶-7在卵巢浆液性肿瘤中的表达

目的：探讨MMP－7在卵巢浆液性肿瘤中的表达情况。方法：采用免疫组化SP法对6例正常卵巢、12例卵巢浆液性囊腺瘤、6例交界性囊腺瘤及22例卵巢浆液性囊腺癌MMP－7的表达进行了研究。结果：正常卵巢不表达MMP－7。大部分卵巢浆液性肿瘤的胞浆及间质中都有MMP－7的阳性表达。MMP－7的卵巢良性，恶性及交界性浆液性肿瘤胞浆中的表达无明显差异；而在肿瘤间质中，恶性及交界性卵巢浆液性肿瘤中的表达远高于良性肿瘤（P＜0．05）。在交界性及恶性浆液性卵巢肿瘤中，部分肿瘤细胞的细胞核中也有MMP－7的表达，为国内外首次报道。结论：MMP－7可能在卵巢浆液性肿瘤的进展中发挥重要作用。     

卵巢肿瘤169例临床分析

目的：探讨卵巢肿瘤的临床特点,以期对其进行早期诊断、早期治疗并改善预后。方法：对我院5年间收治的卵巢肿瘤169例的临床资料进行回顾性分析．其中采用保守性手术治疗157例（92．90％）,根治性手术治疗9例（5．33％）,减瘤术治疗3例（1．78％）。结果：169例卵巢肿瘤患者中,良性、交界性及恶性肿瘤分别为155例（91．71％）、3例（1．78％）、11例（6．51％）。55岁及以上年龄组恶性肿瘤发病率14．29％,高于55岁以下组的4．48％（P〈0．05）。良性及交界性肿瘤治愈率为100％,恶性肿瘤11例中死亡4例（36．36％）：结论：卵巢肿瘤发病多较隐匿,定期作妇科检查及普查普治,对该病的早期诊断、治疗和改善预后有重要意义。     

p73基因在卵巢上皮性肿瘤中的表达及甲基化研究

目的 探讨卵巢上皮性肿瘤中p73蛋白的表达和基因启动子的甲基化情况,并观察其与临床病理学特征的关系.方法 制备包括68例卵巢癌、37例卵巢交界性肿瘤和21例卵巢良性肿瘤的组织芯片,用免疫组织化学EnVision法检测上述组织中p73蛋白表达情况,用亚硫酸氧盐修饰后测序法检测13例新鲜卵巢癌组织及5例新鲜卵巢交界性肿瘤组织的p73基因启动子甲基化情况.结果 92.6％ (63/68)的卵巢癌表达p73,p73蛋白总体表达率均值为32％(p73表达率指p73阳性细胞数所占的百分比),其中浆液性癌( 26/26)的表达率均值为40％,高于其他组织类型的癌(P=0.006).按照卵巢癌发病模式区分,Ⅱ型卵巢癌p73表达率均值(40％)高于Ⅰ型卵巢癌(24％),P=0.010.卵巢癌中p73的表达与临床分期及组织学分级无相关性(均P＞0.05).卵巢交界性肿瘤组(30/37)和良性肿瘤组(12/21)p73的总体表达率均值分别为16％和15％,该两组肿瘤中浆液性肿瘤表达率均值均高于黏液性肿瘤(P-0.003,P=0.026).卵巢癌组的p73阳性表达率均值明显高于交界性肿瘤组和良性肿瘤组(均P ＜0.05),交界性肿瘤组与良性肿瘤组比较差异无统计学意义(P＞0.05).浆液性肿瘤( 49/53)中,卵巢癌组(26/26) p73阳性表达率均值明显高于交界性肿瘤组(12/14)和良性肿瘤组(11/13;P =0.024和P=0.002),而卵巢交界性肿瘤组和良性肿瘤组比较差异无统计学意义(P=0.428).黏液性肿瘤(15/27)中,卵巢癌组(6/7)p73阳性表达率均值高于良性肿瘤组( 1/8;p=0.032),而卵巢癌组与卵巢交界性肿瘤组(8/12)、交界性肿瘤组与良性肿瘤组比较,差异均无统计学意义(P=0.234和P=0.201).p73启动子的甲基化结果显示,13例卵巢癌有8例发生甲基化,但每例样本甲基化频率有所不同,总体甲基化频率均值为8.0％.5例交界性肿瘤有2例发生甲基化,总体甲基化频率均值为9.0％,两组比较差异无统计学意义(P＞0.05).卵巢癌组p73甲基化额率与组织类型、发病模式、组织学分级及临床分期均无相关性(均P＞0.05).结论 卵巢上皮性肿瘤多数表达p73,卵巢癌p73的表达率均值明显高于交界性肿瘤和良性肿瘤,浆液性肿瘤高于其他组织类型;p73蛋白表达率与p73基因甲基化程度不存在简单线性相关关系.     

卵巢肿瘤组织中端粒酶逆转录酶的原位表达

目的　探讨卵巢肿瘤组织中端粒酶逆转录酶 (TRT)的表达及其与凋亡基因 p5 3蛋白和bcl 2基因的关系。方法　应用免疫组织化学S P法检测 78例卵巢肿瘤组织中TRT及p5 3、bcl 2的表达 ,结果进行统计学分析。结果　TRT在不同卵巢肿瘤组中的表达差异有显著性 ,在卵巢上皮组织肿瘤中良性、交界性和恶性肿瘤组的阳性表达分别为 6 7%、5 7 2 %和 85 % ,在卵巢生殖细胞肿瘤中良性与恶性的阳性表达为 10 %和 81 8% ,TRT的表达随着肿瘤恶性度增高呈现阳性率和阳性强度递增现象 ,两者比较差异有显著性 (P <0 0 1) ;卵巢恶性上皮组织肿瘤中 p5 3蛋白和bcl 2基因的阳性表达率分别为 90 %和80 % ,相关分析显示TRT与 p5 3和bcl 2的表达密切相关 (P <0 0 1)。结论　TRT的高表达与卵巢恶性肿瘤有密切关系 ,卵巢肿瘤组织中TRT与p5 3、bcl 2的表达呈正相关 ,TRT可作为卵巢肿瘤恶性度的一个指标。     

端粒酶转录酶及其调节相关蛋白与增殖细胞核抗原在卵巢上皮性肿瘤中的表达及临床意义

目的　探讨端粒酶转录酶 (hTERT)及端粒酶调节相关蛋白 (TRAP)与增殖细胞核抗原(PCNA)在卵巢上皮性肿瘤中的表达和临床意义。方法　收集 10 6例卵巢上皮性肿瘤 (恶性 5 4例 ,交界性 33例 ,良性 19例 )的临床资料 ,行hTERT、TRAP和PCNA 3种抗体的免疫组织化学标记链霉素卵白素生物素 (LSAB)法染色。对 87例恶性和交界性患者进行了随访 ,4 5例获结果 ,随访时间为 2～6 0个月。结果　hTERT蛋白的表达在良性 (4/ 19)和交界性 (90 9% ,30 / 33)以及良性和恶性(94 4 % ,5 1/ 5 4 )间的差异均有显著性 (P均 <0 0 0 1) ,TRAP蛋白的表达在良性 (4/ 15 )和恶性(77 8% ,2 8/ 36 )间的差异有显著性 (P <0 0 0 1) ;hTERT和TRAP蛋白的表达在卵巢癌Ⅰ、Ⅱ期和Ⅲ、Ⅳ期两组病例中的差异均无显著性 (P >0 0 5 ,P >0 3)。PCNA的表达在良性 (6 9± 5 9) %和交界性 (2 6 4± 17 8) %、良性和恶性 (5 1 8± 2 2 1) %以及交界性和恶性间的差异均有显著性 (P <0 0 1,P <0 0 0 1,P <0 0 5 )。 33例交界性患者全部存活 ,5 4例恶性患者中 35例 (6 4 8% )有转移 (包括 5例淋巴结转移 ) ,4例 (7 4 % )死亡。结论　hTERT和TRAP蛋白的表达与卵巢上皮性肿瘤的良恶性有关 ,但与其临床分期无关 ;hTERT和TRAP蛋白的表达相似     

Fascin and EMMPRIN expression in primary mucinous tumors of ovary: A tissue microarray study

ObjectivesThe aim of this study was to compare the expressions of fascin and EMMPRIN in primary malignant, borderline and benign mucinous ovarian tumors, and to investigate the relationship of these markers with tumor progression and their applicability to differential diagnosis.Materials and methodsAn immunohistochemical study was performed for fascin and EMMPRIN using the tissue microarray technique. Eighty-one cases were included in the study; there were 37 benign, 25 borderline and 19 malignant primary mucinous ovarian tumors. For each case, a total staining score was determined, consisting of scores for extent of staining and intensity of staining. The cases were allocated to negative, weakly positive and strongly positive staining categories, according to the total staining score.ResultsBoth of the markers were significantly negative in benign tumors as compared with borderline and malignant tumors. There was no significant difference between borderline and malignant groups for both markers. Sixty-eight percent of malignant tumors were stained positive by fascin, while this rate was 40% for borderline mucinous tumors. All malignant tumors were strongly stained positive for EMMPRIN, while this rate was 92% for borderline mucinous tumors. The rest of the cases stained weakly positive. No significant difference in staining score was found between fascin and EMMPRIN expression.ConclusionsIn ovarian primary mucinous tumors, fascin and EMMPRIN may play an important role in tumor progression from benign tumor to carcinoma. In that context, EMMPRIN and fascin expression may have potential application in the differential diagnosis of some diagnostically problematic mucinous ovarian tumors. However, the differential diagnostic applicability of EMMPRIN appears to be more limited than that of fascin due to its wide spectrum of staining in mucinous ovarian tumors.     

Increased staining for phosphorylated AKT and nuclear factor‐κB p65 and their relationship with prognosis in epithelial ovarian cancer

AKT plays an important role in malignant behavior of tumors. The purpose of the present study was to determine the expression of phosphorylated AKT (P‐AKT) and nuclear factor‐κB (NF‐κB) p65 and their association with clinicopathological parameters and prognosis in epithelial ovarian tumor. On immunohistochemistry 115 samples of ovarian tissue that included 68 specimens of epithelial ovarian cancer, 12 of borderline tumor, 24 of epithelial benign tumor and 11 of normal ovary, were evaluated. Sixty‐three patients with ovarian cancer were followed up from 7 to 68 months. The positive expression rate of P‐AKT and NF‐κB p65 were higher in epithelial ovarian cancer than in normal ovarian tissue (P < 0.01). Elevated P‐AKT or NF‐κB p65 expression was significantly correlated with late clinical stage (P < 0.05 and P < 0.01) and poor histological differentiation (both P < 0.01). P‐AKT expression was significantly correlated with NF‐κB p65 immunostaining (φ = 0.272, P < 0.05). Elevated expression of P‐AKT was negatively correlated with the survival of ovarian cancer patients, but it was not an independent prognostic factor after multivariate analysis. Overexpression of P‐AKT and NF‐κB p65 were involved in the carcinogenesis and metastasis of ovarian cancer. P‐AKT might contribute to the malignant transformation through NF‐κBp65 upregulation.     

ROBO4在上皮性卵巢癌组织和血清中的表达及临床意义

目的 探讨ROBO4在上皮性卵巢癌组织和血清中的表达及其在卵巢癌发生发展中的作用。方法 采用免疫组织化学和反转录聚合酶链反应（RT-PCR）方法检测110例卵巢癌,54例卵巢良性肿瘤,40例正常卵巢组织中ROBO4蛋白和ROBO4mRNA表达,比较其表达与卵巢癌临床病理特征的关系;并采用ELISA检测卵巢癌、卵巢良性肿瘤和正常人血清中ROBO4表达水平。结果 卵巢癌组织中ROBO4蛋白和ROBO4mRNA表达显著低于正常对照组和卵巢良性肿瘤组（P<0.05）;上皮性卵巢癌血清中ROBO4的表达明显低于卵巢良性肿瘤和正常人（P<0.05）;卵巢癌组织中ROBO4表达降低与卵巢癌FIGO分期、淋巴结转移、大网膜转移和腹水相关（P<0.05）;卵巢癌组织中ROBO4表达与年龄、组织学类型和病理分级无相关性。卵巢癌患者血清ROBO4、CA125的相关分析显示,两者之间无相关性。结论 在卵巢癌发生过程中ROBO4表达降低起到重要作用,表达异常的ROBO4与卵巢癌的侵袭转移能力相关,并与卵巢癌的临床病理学特征有明显的相关性。     

Expression of Fas and FasL in human serous ovarian epithelial tumors

The expression of Fas and FasL was studied in 86 patients with benign, borderline, and malignant serous ovarian lesions. Four normal ovaries, and monolayer epithelial cultures from a human fetal ovary, a borderline, and a serous adenocarcinoma were used for comparison. Expression of Fas and FasL was studied immunohistochemically and flowcytometrically. Fas was expressed in all 90 lesions; FasL in 57 lesions, including 2 normal ovaries. Fas expression was significantly increased in borderline tumors compared with benign (P = 0.005, t = -2.94) or malignant serous tumors (P = 0.0001, t = 4.15). FasL expression was significantly increased in malignant tumors compared with benign (P = 0.039, t = -2.10) and borderline tumors (P = 0.0016, t = -3.33). Flow cytometry showed a range of Fas expression in short-term cultures isolated from normal, borderline, and malignant ovarian serous tissue; in the few samples studied, FasL was not expressed. Expression in three serous ovarian cell lines was similar. Fas and FasL expression differed throughout the spectrum of ovarian lesions. FasL expression was increased in malignant tumors, and Fas expression was increased in borderline tumors. Changes in Fas/FasL expression in ovarian surface epithelium might play a functional role in the biology of ovarian tumors.     

Comparison of c-met Expression in Ovarian Epithelial Tumors and Normal Epithelia of the Female Reproductive Tract by Quantitative Laser Scan Microscopy

The transmembrane tyrosine kinase receptor c-met with its ligand, hepatocyte growth factor/scatter factor (HGF/SF), acts as a mitogen, motogen, and morphogen in many normal epithelia. HGF/SF-met signaling has also been implicated in neoplastic progression and metastasis. In this study, immunofluorescence staining and quantitative laser scanning confocal microscopy were used to measure c-met expression in ovarian surface epithelial tumors from 17 oophorectomy specimens. These specimens were from patients aged 25 to 81 (mean age, 52) and included 10 malignant tumors, 4 borderline tumors, and five benign tumors including a Brenner tumor. For comparison, c-met expression was measured in normal tissues from the same patients, including 4 ovarian surface epithelia, 4 fallopian tube epithelia, 2 endometria, and 3 endocervical epithelia, as well as 3 cases of endometriosis. Relative pixel intensity values of c-met expression ranged from 0.4 in a normal ovarian surface epithelium to 22.3 in a borderline serous tumor. Malignant tumors (mean, 9.6) and borderline tumors (mean, 12.9) had higher average c-met expression levels than normal tissues (mean, 3.6) and endometriosis (mean, 1.8). The expression levels of benign tumors were intermediate (mean, 7.9). Among the normal tissues, c-met expression in fallopian tubes (mean, 8.2; range, 3.4-12.9) was higher than that of the other normal epithelia (mean, 1.6; range, 0.4-4.3). In eight cases where both normal and malignant tissues were sampled, c-met expression was significantly greater in malignant than in normal epithelia (P = 0.01). These findings indicate that c-met plays a role in the biology of the normal tissues examined. They confirm that its expression increases in the malignant progression of ovarian surface epithelial tumors, and suggest that increases comparable to those in frankly malignant carcinomas have already been reached in borderline lesions, ie, early in the neoplastic process.     

血管内皮生长因子及其受体在卵巢癌中表达的免疫组化检测

目的： 检测血管内皮生长因子（ＶＥＧＦ） 及其受体（ＫＤＲ） 在卵巢癌中的表达, 并探讨其与卵巢癌发生的关系。方法： 采用ＳＡＢＣ免疫组化染色法, 对６６ 例卵巢肿瘤中, ＶＥＧＦ 和ＫＤＲ 的表达进行检测。结果： 恶性、交界性及良性卵巢肿瘤中, ＶＥＧＦ 和ＫＤＲ 的表达率分别为７２－９％ 、７５－００ ％ 、３８－４６ ％ 及５４－０５％ 、４３－７５％ 、７－６９ ％ ; 恶性肿瘤及交界性肿瘤ＶＥＧＦ和ＫＤＲ的表达, 明显高于良性肿瘤（Ｐ＜ ０－０５） 。ＫＤＲ 不仅表达于肿瘤血管内皮细胞, 在肿瘤细胞内也有强表达。有淋巴结转移的卵巢癌ＶＥＧＦ 的表达与无淋巴结转移者相比较, 有显著差异（Ｐ＜ ０－０５）; ＫＤＲ 的表达与卵巢癌淋巴结转移无关（Ｐ＞ ０－０５）; 卵巢癌的不同临床分期、病理类型及病理分级间ＶＥＧＦ和ＫＤＲ的表达, 无显著性差异（ Ｐ＞ ０－０５） 。结论： ＶＥＧＦ和ＫＤＲ 的表达可能与卵巢癌的发生有关。